التفاصيل البيبلوغرافية
| العنوان: |
The role of alprazolam for the treatment of panic disorder in Australia. |
| المؤلفون: |
Moylan, Steven, Giorlando, Francesco, Nordfjærn, Trond, Berk, Michael |
| المصدر: |
Australian & New Zealand Journal of Psychiatry; Mar2012, Vol. 46 Issue 3, p212-224, 13p |
| مصطلحات موضوعية: |
ALPRAZOLAM, DRUG addiction, DRUG utilization, DRUG withdrawal symptoms, DRUGS, DRUG prescribing, MEDICAL information storage & retrieval systems, PSYCHOLOGY information storage & retrieval systems, MEDICAL protocols, MEDLINE, HEALTH outcome assessment, PANIC disorders, SYSTEMATIC reviews, PHYSICIAN practice patterns, TREATMENT effectiveness, PATIENTS' attitudes, PHYSICIANS' attitudes, THERAPEUTICS |
| مصطلحات جغرافية: |
AUSTRALIA |
| مستخلص: |
Objective: To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature.Methods: Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles. Clinical practice guidelines from the American Psychiatric Association, National Institute of Clinical Excellence, Royal Australian and New Zealand College of Psychiatrists and World Federation of Societies of Biological Psychiatry were sourced. Prescription data were sourced from Australian governmental sources.Results: Alprazolam has shown efficacy for control of PD symptoms, particularly in short-term controlled clinical trials, but is no longer recommended as a first-line pharmacological treatment due to concerns about the risks of developing tolerance, dependence and abuse potential. Almost no evidence is available comparing alprazolam to current first-line pharmacological treatment. Despite this, prescription rates are increasing. A number of potential issues including use in overdose and impact on car accidents are noted.Conclusion: Although effective for PD symptoms in clinical trials, a number of potential issues may exist with use. Consideration of its future place in PD treatment in Australia may be warranted. [ABSTRACT FROM PUBLISHER] |
|
Copyright of Australian & New Zealand Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
